MX2022006276A - Metodos de tratamiento del cancer. - Google Patents

Metodos de tratamiento del cancer.

Info

Publication number
MX2022006276A
MX2022006276A MX2022006276A MX2022006276A MX2022006276A MX 2022006276 A MX2022006276 A MX 2022006276A MX 2022006276 A MX2022006276 A MX 2022006276A MX 2022006276 A MX2022006276 A MX 2022006276A MX 2022006276 A MX2022006276 A MX 2022006276A
Authority
MX
Mexico
Prior art keywords
adenosine
methods
inhibitor
treating cancer
signalling
Prior art date
Application number
MX2022006276A
Other languages
English (en)
Inventor
Kris Sachsenmeier
Benjamin Sidders
Robert D Mulla
Natalya Markuzon
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2022006276A publication Critical patent/MX2022006276A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En el presente documento se describen métodos para identificar cánceres inducidos por adenosina. Los métodos incluyen la determinación de una puntuación de firma de la señalización de adenosina tumoral. La puntuación de firma refleja los niveles de expresión de un grupo de genes de firma cuyo patrón de niveles de expresión es indicativo de una elevada señalización de adenosina. Los cánceres inducidos por adenosina pueden ser susceptibles al tratamiento con un inhibidor de la señalización de adenosina, tal como un inhibidor de CD39, un inhibidor de CD73 o un antagonista de receptores de adenosina. También se describen métodos de tratamiento del cáncer.
MX2022006276A 2019-11-26 2020-11-25 Metodos de tratamiento del cancer. MX2022006276A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962940329P 2019-11-26 2019-11-26
PCT/EP2020/083397 WO2021105232A1 (en) 2019-11-26 2020-11-25 Methods of treating cancer

Publications (1)

Publication Number Publication Date
MX2022006276A true MX2022006276A (es) 2022-08-15

Family

ID=73598135

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006276A MX2022006276A (es) 2019-11-26 2020-11-25 Metodos de tratamiento del cancer.

Country Status (7)

Country Link
US (1) US20230332239A1 (es)
KR (1) KR20220105160A (es)
AU (1) AU2020394514A1 (es)
BR (1) BR112022009909A2 (es)
CA (1) CA3161177A1 (es)
MX (1) MX2022006276A (es)
WO (1) WO2021105232A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3009527C (en) * 2015-12-24 2024-01-09 Stephen WILLINGHAM Methods of treating cancer
EP3606531A4 (en) * 2017-04-04 2021-04-28 Corvus Pharmaceuticals, Inc. CANCER TREATMENT METHODS
TW202012637A (zh) * 2018-04-24 2020-04-01 瑞典商阿斯特捷利康公司 治療癌症之方法
US20210255190A1 (en) * 2018-07-12 2021-08-19 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
EP3820522A4 (en) * 2018-07-12 2022-05-18 Corvus Pharmaceuticals, Inc. METHODS FOR DETECTING AND TREATING CANCERS HAVING ACTIVATION OF THE ADENOSINE PATHWAY
MX2021008094A (es) * 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.

Also Published As

Publication number Publication date
BR112022009909A2 (pt) 2022-08-09
US20230332239A1 (en) 2023-10-19
CA3161177A1 (en) 2021-06-03
WO2021105232A1 (en) 2021-06-03
AU2020394514A1 (en) 2022-07-07
KR20220105160A (ko) 2022-07-26

Similar Documents

Publication Publication Date Title
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
CY1122651T1 (el) Μεθοδοι και συνθεσεις για προσδιορισμο της αντιστασης εναντι θεραπειας υποδοχεα ανδρογονου
CY1122247T1 (el) Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3
PH12020551195A1 (en) Methods and compositions for macrophage polarization
MX2017013794A (es) Métodos para tratar el cáncer.
MX2021014177A (es) Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.
MY183036A (en) Amino-triazolopyridine compounds and their use in treating cancer
WO2016196298A8 (en) Therapeutic and diagnostic methods for cancer
MX2023001945A (es) Composiciones y metodos para el cribado de tumores solidos.
MX2013004086A (es) Metodos para inhibir proliferacion celular en cancers accionados por egfr.
JOP20200315A1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
BR112017020336A2 (pt) análogos de nucleosídeos 5?-substituídos
RU2014110228A (ru) Диагностические маркеры
MX2021006734A (es) Metodo para tratar el cancer.
WO2005113816A3 (en) Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
MX2017007535A (es) Sistema y metodos para derivar biomarcadores de firmas geneticas de la respuesta a antagonistas de muerte programada 1 (pd-1).
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
MX2016017407A (es) Inhibidores de histona demetilasa.
MX2017012824A (es) Tratamiento de cáncer de pulmón con inhibidores de glutaminasa.
BR112014024017A8 (pt) Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
BR112022003165A2 (pt) Método de tratamento de cânceres associados a kras
MX2019012741A (es) Biomarcadores para agentes terapeuticos contra el cancer.
MX2017003466A (es) Inhibidores de histona desmetilasa.